Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
eLife · 2025
DOI: 10.7554/elife.101583 ↗Kurz gefasst
Klinische Studie in der Zeitschrift eLife, 2025. Verfasst von Yu Zhang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Androstadienes, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates and moderate objective response rates (ORR) in hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. With proven synergistic effect of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and radiotherapy in preclinical studies, this pilot study aimed to explore the efficacy and safety of neoadjuvant stereotactic body radiation therapy (SBRT) followed by dalpiciclib and exemestane in HR-positive, HER2-negative breast cancer.
Methods
This was a single-arm, non-controlled prospective pilot study. Treatment-naive patients with unilateral HR-positive, HER2-negative breast cancer received neoadjuvant radiotherapy (24 Gy/3 F) followed by dalpiciclib and exemestane for six cycles. The primary endpoint was the proportion of patients with residual cancer burden (RCB) score of 0-I. Key secondary endpoints included ORR, breast-conservation rate, biomarker analysis, and safety.
Results
All 12 enrolled patients completed the study treatment and surgery. Two (16.7%) of them achieved the RCB 0-I with the ORR of 91.7% (11/12). Analyses of tumor specimens showed significant increase of infiltrating T cells rather than alteration of PD-L1 positive immune cells. The most common grade 3 adverse events (AEs) were neutropenia (66.7%) and leukopenia (25.0%), but no grade 4–5 AE or death occurred.
Conclusions
Our results suggested neoadjuvant SBRT followed by dalpiciclib and exemestane is effective and tolerable and provides novel insights for the neoadjuvant treatment of HR+/HER2- breast cancer, which may be considered as a feasible option for patients with HR-positive, HER2-negative breast cancer. Funding: None. Clinical trial number: ClinicalTrials.gov: NCT05132790
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
- Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
- Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China.
- Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
- Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, China.
- Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
ORCID-Profile: Nan Niu, Yongliang Yang, Caigang Liu
Zitieren
APA
Zhang, Y., Cao, S., Niu, N., Shan, H., Xue, J., Chen, G., Xu, Y., Yin, J., Liu, C., Sun, L., Jiang, X., Tang, M., Xu, Q., Jia, M., Zhang, X., Zhang, Z., Zhang, Q., Wang, J., Li, A., …, & Liu, C. (2025). Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study. eLife. https://doi.org/10.7554/elife.101583
Vancouver
Zhang Y, Cao S, Niu N, Shan H, Xue J, Chen G, et al. Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study. eLife. 2025. doi:10.7554/elife.101583
BibTeX
@article{Zhang2025,
author = {Zhang, Yu and Cao, Shuo and Niu, Nan and Shan, Huilian and Xue, Jinqi and Chen, Guanglei and Xu, Yongqing and Yin, Jianqiao and Liu, Chao and Sun, Lisha and Jiang, Xiaofan and Tang, Meiyue and Xu, Qianshi and Jia, Mingxuan and Zhang, Xu and Zhang, Zhenyong and Zhang, Qingfu and Wang, Jianfei and Li, Ailin and Yang, Yongliang and Liu, Caigang},
title = {Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.101583}
}
EUVIMED